Empaglin Duo Tablet 12.5/850 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
MFDS item code 202302756 · Approved 2023.09.14
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used as an adjunct to diet and exercise to improve blood sugar control in adult patients with type 2 diabetes. In particular, it helps with blood sugar management by combining empagliflozin and metformin. Caution is necessary for patients with cardiovascular disease among those whose blood sugar is not adequately controlled, and professional guidance should be sought. This drug is designed to have a positive impact on cardiovascular health alongside effective blood sugar control.
The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended dose when taking this drug is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This drug should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this drug, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 3, item 1) Patients Requiring Caution in Administration under Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see item 2) under section 2. Patients in Whom the Drug Must Not Be Administered in Precautions for Use). Elderly Patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This drug can cause a rare but serious side effect known as lactic acidosis, so caution is required during use. When used with other diabetes medications, hypoglycemia can occur, so blood sugar levels should be monitored closely. Patients with moderate to severe renal impairment, acute kidney issues, severe infections, or rapidly deteriorating heart function should not use this drug. Pregnant or breastfeeding women must not take this drug. This medication should be temporarily discontinued before and after tests using iodine contrast agents, and can be resumed once renal function has returned to normal. Patients scheduled for surgery, particularly those requiring general anesthesia, should discontinue this drug 48 hours prior to the procedure and can resume once normal renal function is confirmed post-surgery. Patients at risk of fluid loss, the elderly, or those showing signs of dehydration should monitor their hydration status and blood pressure closely during use. During treatment with this drug, regular monitoring of blood sugar control is essential, and immediate consultation with healthcare professionals is necessary if symptoms of hypoglycemia or infection appear. Additionally, this drug may lower vitamin B12 levels, so it is advisable to check nutritional status with regular blood tests. Alcohol consumption can increase the risk of side effects from this drug, so excessive drinking should be avoided during treatment. Caution may be needed when driving or operating machinery while taking this medication, depending on symptoms. This drug is not recommended for children under 18, and dosage adjustments may be necessary for the elderly based on renal function. In case of overdose, immediate medical attention is required, and prompt treatment is especially necessary if lactic acidosis symptoms are suspected. Lastly, keep this drug out of reach of children and store it in its original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to prevent air or moisture from entering, and it is preferable to keep it at room temperature between 1 degree and 30 degrees Celsius. Proper storage helps maintain the drug's effectiveness.
A white, oval, biconvex film-coated tablet with a pinkish hue
10 tablets/box [(10 tablets/PTP×1)], 60 tablets/box [(10 tablets/PTP×6)], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.